Sermorelin, a growth hormone-releasing hormone analog, and tirzepatide, a dual GLP-1/GIP receptor agonist, target distinct metabolic pathways that may work synergistically
For many patients who experience fatigue when starting GLP-1 therapy, symptoms often improve as the body adapts to the medication
Theres no need to taper off gradually
In conclusion, this trial demonstrates the superiority of oral semaglutide vs sitagliptin in reducing HbA 1c and body weight from baseline in a predominantly Chinese population with type 2 diabetes, as well as a safety and tolerability profile for semaglutide that is consistent with that of the GLP-1RA class
Exploring FDA-approved frontiers: Insights into natural and engineered peptide analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and -MSH realms